☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Seres Therapeutics
Seres Therapeutics and Nestlé Health Science Present P-III Study (ECOSPOR IV) Results Vowst for Prevention of Recurrence of C. Dif...
May 9, 2023
Seres Therapeutics and Nestlé Health Science Receive the US FDA’s Approval of VOWST for the Prevention of Recurrence of C. Diffici...
April 27, 2023
Seres Therapeutics Reports P-III Trial (ECOSPOR IV) Results of SER-109 for the Prevention of Recurrent C. Difficile Infection
February 15, 2023
Load more...
Back to Home
Modal title
×
Modal body text goes here.